Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (Q46250024)

20 December 2017

title

Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (English)

1 reference

20 December 2017

0 references

0 references

1 reference

C Sachse-Seeboth

1

1 reference

20 December 2017

J Pfeil

2

1 reference

20 December 2017

D Sehrt

3

1 reference

20 December 2017

I Meineke

4

1 reference

20 December 2017

M Tzvetkov

5

1 reference

20 December 2017

E Bruns

6

1 reference

20 December 2017

W Poser

7

1 reference

20 December 2017

S V Vormfelde

8

1 reference

20 December 2017

J Brockmöller

9

1 reference

20 December 2017

language of work or name

English

0 references

publication date

12 November 2008

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

85

1 reference

20 December 2017

page(s)

273-276

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

Therapeutic potential of cannabinoids in CNS disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Discovery of new potentially defective alleles of human CYP2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Concentration of drugs in blood of suspected impaired drivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Pharmacokinetics of 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

Chemical basis of hashish activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

Impairment in drivers due to cannabis in combination with other drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

Relationship between THC concentration in blood and impairment in apprehended drivers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.213

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.213

1 reference

20 December 2017

PubMed ID

19005461

1 reference

20 December 2017